Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 10,470 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $70.00, for a total transaction of $732,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Scott Biller also recently made the following trade(s):

  • On Monday, October 2nd, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $67.23, for a total transaction of $144,275.58.
  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.00, for a total transaction of $975,000.00.
  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54.
  • On Wednesday, August 2nd, Scott Biller sold 23,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $59.60, for a total transaction of $1,379,501.60.
  • On Friday, July 7th, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $55.00, for a total transaction of $118,030.00.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 0.81% during trading on Thursday, hitting $70.82. 320,924 shares of the company were exchanged. The stock’s market capitalization is $3.43 billion. The firm’s 50 day moving average price is $63.02 and its 200-day moving average price is $55.90. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $71.40.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. During the same quarter last year, the company earned ($1.47) EPS. The business’s revenue was up 62.1% compared to the same quarter last year. Equities analysts predict that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current year.

WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Insider Sells $732,900.00 in Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/05/agios-pharmaceuticals-inc-agio-insider-sells-732900-00-in-stock.html.

A number of large investors have recently modified their holdings of the stock. Bank of Montreal Can increased its holdings in Agios Pharmaceuticals by 11.7% in the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the period. Creative Planning increased its holdings in Agios Pharmaceuticals by 1.4% in the 2nd quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 228 shares during the period. Public Employees Retirement Association of Colorado increased its holdings in Agios Pharmaceuticals by 5.2% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 323 shares during the period. BNP Paribas Arbitrage SA increased its holdings in Agios Pharmaceuticals by 2.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,575 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 385 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in Agios Pharmaceuticals by 9.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 425 shares during the period. Institutional investors own 94.40% of the company’s stock.

AGIO has been the subject of a number of analyst reports. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, June 11th. Cann restated a “buy” rating and set a $75.00 price objective on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.20.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.